Format
Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 62

1.

Oligomeric α-synuclein and β-amyloid variants as potential biomarkers for Parkinson's and Alzheimer's diseases.

Williams SM, Schulz P, Sierks MR.

Eur J Neurosci. 2016 Jan;43(1):3-16. doi: 10.1111/ejn.13056. Epub 2015 Oct 15.

PMID:
26332448
2.

Toxic Oligomeric Alpha-Synuclein Variants Present in Human Parkinson's Disease Brains Are Differentially Generated in Mammalian Cell Models.

Xin W, Emadi S, Williams S, Liu Q, Schulz P, He P, Alam NB, Wu J, Sierks MR.

Biomolecules. 2015 Jul 22;5(3):1634-51. doi: 10.3390/biom5031634.

3.

A novel nicotinic mechanism underlies β-amyloid-induced neurotoxicity.

Liu Q, Xie X, Emadi S, Sierks MR, Wu J.

Neuropharmacology. 2015 Oct;97:457-63. doi: 10.1016/j.neuropharm.2015.04.025. Epub 2015 May 7.

PMID:
25959067
4.

Novel atomic force microscopy based biopanning for isolation of morphology specific reagents against TDP-43 variants in amyotrophic lateral sclerosis.

Williams SM, Venkataraman L, Tian H, Khan G, Harris BT, Sierks MR.

J Vis Exp. 2015 Feb 12;(96). doi: 10.3791/52584.

PMID:
25742170
5.

Isolation and characterization of antibody fragments selective for toxic oligomeric tau.

Tian H, Davidowitz E, Lopez P, He P, Schulz P, Moe J, Sierks MR.

Neurobiol Aging. 2015 Mar;36(3):1342-55. doi: 10.1016/j.neurobiolaging.2014.12.002. Epub 2014 Dec 11.

6.

A sensitive phage-based capture ELISA for sub-femtomolar detection of protein variants directly from biological samples.

Williams S, Schulz P, Sierks MR.

Biotechnol Prog. 2015 Jan-Feb;31(1):289-98. doi: 10.1002/btpr.1987. Epub 2014 Sep 23.

PMID:
25203940
7.

Human α4β2 nicotinic acetylcholine receptor as a novel target of oligomeric α-synuclein.

Liu Q, Emadi S, Shen JX, Sierks MR, Wu J.

PLoS One. 2013;8(2):e55886. doi: 10.1371/journal.pone.0055886. Epub 2013 Feb 20.

8.

Isolation and characterization of antibody fragments selective for specific protein morphologies from nanogram antigen samples.

Kasturirangan S, Reasoner T, Schulz P, Boddapati S, Emadi S, Valla J, Sierks MR.

Biotechnol Prog. 2013 Mar-Apr;29(2):463-71. doi: 10.1002/btpr.1698. Epub 2013 Mar 7.

9.

Bispecific tandem single chain antibody simultaneously inhibits β-secretase and promotes α-secretase processing of AβPP.

Boddapati S, Levites Y, Suryadi V, Kasturirangan S, Sierks MR.

J Alzheimers Dis. 2012;28(4):961-9. doi: 10.3233/JAD-2011-111196.

PMID:
22156046
10.

CSF levels of oligomeric alpha-synuclein and beta-amyloid as biomarkers for neurodegenerative disease.

Sierks MR, Chatterjee G, McGraw C, Kasturirangan S, Schulz P, Prasad S.

Integr Biol (Camb). 2011 Dec;3(12):1188-96. doi: 10.1039/c1ib00018g. Epub 2011 Nov 10.

11.

Inhibiting β-secretase activity in Alzheimer's disease cell models with single-chain antibodies specifically targeting APP.

Boddapati S, Levites Y, Sierks MR.

J Mol Biol. 2011 Jan 14;405(2):436-47. doi: 10.1016/j.jmb.2010.10.054. Epub 2010 Nov 10.

PMID:
21073877
12.

Nanobody specific for oligomeric β-amyloid stabilizes nontoxic form.

Kasturirangan S, Li L, Emadi S, Boddapati S, Schulz P, Sierks MR.

Neurobiol Aging. 2012 Jul;33(7):1320-8. doi: 10.1016/j.neurobiolaging.2010.09.020. Epub 2010 Nov 9.

PMID:
21067847
13.

Curcumin reduces alpha-synuclein induced cytotoxicity in Parkinson's disease cell model.

Wang MS, Boddapati S, Emadi S, Sierks MR.

BMC Neurosci. 2010 Apr 30;11:57. doi: 10.1186/1471-2202-11-57.

14.

Engineered proteolytic nanobodies reduce Abeta burden and ameliorate Abeta-induced cytotoxicity.

Kasturirangan S, Boddapati S, Sierks MR.

Biochemistry. 2010 Jun 1;49(21):4501-8. doi: 10.1021/bi902030m.

PMID:
20429609
15.

Physico-chemical determinants of soluble intrabody expression in mammalian cell cytoplasm.

Kvam E, Sierks MR, Shoemaker CB, Messer A.

Protein Eng Des Sel. 2010 Jun;23(6):489-98. doi: 10.1093/protein/gzq022. Epub 2010 Apr 8.

16.

Antifibrillizing agents catalyze the formation of unstable intermediate aggregates of beta-amyloid.

Wang MS, Boddapati S, Sierks MR.

Biotechnol Prog. 2010 Jul-Aug;26(4):1172-9. doi: 10.1002/btpr.396.

PMID:
20306540
17.

Cyclodextrins promote protein aggregation posing risks for therapeutic applications.

Wang MS, Boddapati S, Sierks MR.

Biochem Biophys Res Commun. 2009 Aug 28;386(3):526-31. doi: 10.1016/j.bbrc.2009.06.077. Epub 2009 Jun 18.

PMID:
19540204
18.

Conformational targeting of fibrillar polyglutamine proteins in live cells escalates aggregation and cytotoxicity.

Kvam E, Nannenga BL, Wang MS, Jia Z, Sierks MR, Messer A.

PLoS One. 2009 May 28;4(5):e5727. doi: 10.1371/journal.pone.0005727.

19.

Intracellular targeting and clearance of oligomeric alpha-synuclein alleviates toxicity in mammalian cells.

Yuan B, Sierks MR.

Neurosci Lett. 2009 Jul 31;459(1):16-8. doi: 10.1016/j.neulet.2009.04.046. Epub 2009 Apr 24.

PMID:
19394405
20.

Detecting morphologically distinct oligomeric forms of alpha-synuclein.

Emadi S, Kasturirangan S, Wang MS, Schulz P, Sierks MR.

J Biol Chem. 2009 Apr 24;284(17):11048-58. doi: 10.1074/jbc.M806559200. Epub 2009 Jan 13.

Items per page

Supplemental Content

Loading ...
Write to the Help Desk